Nicotinic Receptor Ligands and Novel Object Recognition

Callahan, Patrick M.; Terry, Alvin V.

doi:10.1016/b978-0-12-812012-5.00026-4

Cited by 3 publications

(1 citation statement)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, EDV administration managed to improve animals' memory performance in MWM and the discrimination factor in NOR significantly in comparison to AD-like disorder group. In this context, it has been proved that enhancement in the function of peripheral cortex and hippocampus is related to higher rodents' discriminative behavior in NOR [ 30 ]. EDV treatment also demonstrated recovering effect on abnormalities induced by ICV-STZ application, namely regulatory effect on FRAP as a representative of total antioxidant resources and GSH as the main endogenous neural antioxidant.…”

Section: Discussionmentioning

confidence: 99%

Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters

Anoush,

Bijani,

Moslemifar

et al. 2023

Behavioural Neurology

View full text Add to dashboard Cite

Alzheimer’s disease (AD), as the main cause of dementia, has a progressive and neurodegenerative pattern with number of cases increasing over the next decades. Therefore, discovering an effective treatment with the ability to invert memory impairment and pathophysiological events of AD seems to be required. The present study performed to investigate the probable effects of Edaravone (EDV) in AD-like disorder induced by intracerebroventricular streptozotocin (ICV-STZ) administration in mice. This study also compares the two different methods of ICV-STZ in the memory impairment induction. NMRI male mice were administrated with 3 mg/kg of STZ for two times during 48 hours span, and after 24 hours, animals were treated with EDV (5 and 10 mg/kg), Donepezil, and Memantine for 14 days. After behavioral tests regarding memory and cognitive function, animals were sacrificed, and the hippocampi were utilized for further analyses. Our results demonstrated that administration of STZ induced memory impairment in the Morris water maze (MWM) test and decreased the discriminative factor in novel object recognition (NOR). The biochemical output shows a significant decrease in ferric reducing antioxidant power (FRAP) and glutathione (GSH) levels followed by increase in malondialdehyde (MDA) and protein carbonylation (PCO) levels. The output showed no difference between the patterns of AD-like disorder induction. Following our treatment groups, administration of EDV (5 and 10 mg/kg), Donepezil, and Memantine significantly improved memory performance and discriminatory behavior. Aforementioned treatments managed to improve FRAP and GSH content of hippocampus, while significantly attenuating MDA, PCO, and nitric oxide overproduction. In addition, no significant difference has been observed between the effect of 5 and 10 mg/kg EDV application. It was supposed that EDV managed to ameliorate memory dysfunction, discriminatory behavior, oxidative stress, and cellular antioxidant power in a dose-independent pattern in mice.

show abstract

Section: Discussionmentioning

confidence: 99%